<DOC>
	<DOC>NCT00488397</DOC>
	<brief_summary>In-vitro surveillance study of tigecycline (Tygacil) in Taiwan.</brief_summary>
	<brief_title>Tigecycline In-Vitro Surveillance Study In Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Community-Acquired Infections</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<criteria>Clinically relevant causative isolate (no duplicates) The isolate must meet the laboratory criteria of "significant pathogen" and be considered the "probable causative agent" of a hospital or community acquired infection. Sources All body sites are acceptable clinical sources for isolates to be included in this study (Intraabdominal infection, tracheal secretion/bronchoalveolar lavage, blood culture, wound smear). However, no more than 10 % of all isolates can come from urine cultures. Within study group Only isolates defined by the protocol are to be included. Limited isolates from sources No more than 10 % of all isolates from this study will be derived from urine cultures. No banked or stored isolates. No duplicate isolates Only one isolate per patient is permitted. Outside study group Any isolate other than those defined by protocol.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Tygacil</keyword>
	<keyword>microdilution method</keyword>
	<keyword>Tigecycline</keyword>
	<keyword>In-Vitro</keyword>
</DOC>